Clinical data | |
---|---|
Drug class | GABAA receptor inverse agonist |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H14N6O3 |
Molar mass | 326.316 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Ro15-4513 is a weak partial inverse agonist of the benzodiazepine class of drugs, developed by Hoffmann–La Roche in the 1980s.[1] It acts as an inverse agonist (which acts in a similar way as a competitive antagonist), and can therefore be an antidote to the acute impairment caused by alcohols, including ethanol, isopropanol, tert-butyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, methylpentynol, and ethchlorvynol.
Ro15-4513 is structurally related to the benzodiazepine antidote flumazenil.